Modified tuberculosis vaccine as therapy against bladder cancer

March 5, 2020

The Max Planck Insitute for Infection Biology is sharing news of interest to the Immunology Community.

Therapy with VPM1002 is effective in bladder cancer patients

The human immune system can recognize and eliminate not only germs but also cancer cells. This is why treatments with weakened germs can help the immune system it ist fight against cancer.

The Max Planck Insitute for Infection Biology has developed a vaccine against TB which is currently in phase III trial. Less known is that this vaccine is also tested for treatment of bladder cancer and it has now shown a remarkable outcome in a clinical trial in preventing cancer recurrence.

clinical trial no.: NCT02371447 (https://clinicaltrials.gov/ct2/show/NCT02371447)

More News

We have a winner! 2020 Early Career Research Prize in Vaccinology R&D

May 18, 2020Vaccine Committee (VAC)

2020 Edition: Day of Immunology

April 30, 2020

Menarini Prize for Outstanding Woman Immunologist

April 29, 2020Gender Equality Committee (GEC)

Announcement of a New “Travel for Expertise” Travel Grant Program

April 23, 2020Gender Equality Committee (GEC)

Webinar on-demand: Rino Rappuoli on COVID-19 Vaccines

April 8, 2020

Webinar: COVID-19 Vaccines

April 3, 2020

The British Immunological Society launches the “Celebrate Vaccines” campaign on March 26

March 25, 2020

CALL FOR EXPERTS: IUIS-Frontiers in Immunology Webinar Series on COVID-19

March 13, 2020

ASI Invite IUIS Members to Become a Member

February 26, 2020Australian and New Zealand Society for Immunology